Fibrosis-4 index (FIB-4) has been shown to be a prognostic marker of liver-related outcomes in patients with NAFLD. J. Vieira Barbosa et al. (Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA, Lausanne University Hospital and University of Lausanne, Switzerland) analysed data on 30 million patients categorised into three diagnostic groups: NAFLD, NASH, and at risk of NASH.
In this real-world nationwide database, FIB-4 ≥ 2.67 “was a strong predictor of both all-cause mortality and liver-related adverse outcomes independently of the baseline diagnostic group and common risk factors.”
According to the authors’ conclusion, “FIB-4 could play a role as a risk-stratification tool for a population health approach.”